Updated Jul 16, 2026
Dambkowski Carl has filed 7 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $17.97M.
Carl Dambkowski is the Chief Medical Officer at Apogee Therapeutics, Inc., a biotechnology company focused on developing biologics for various inflammatory and immunology conditions. He has been involved in multiple SEC filings related to his role but does not have notable public recognition.
| Role | Chief Medical Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-03 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 5.5K | $132.74 | $730K |
| 2026-07-03 | APGE | Apogee Therapeutics, Inc. | M — Option exercise | 4.1K | $22.86 | $94K |
| 2026-06-25 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 26.4K | $132.60 | $3.50M |
| 2026-06-12 | ORKA | Oruka Therapeutics, Inc. | S — Open-market sale | 12.6K | $70.11 | $882K |
| 2026-06-12 | ORKA | Oruka Therapeutics, Inc. | S — Open-market sale | 22.4K | $70.13 | $1.57M |
| 2026-06-06 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 5.5K | $78.71 | $433K |
| 2026-06-06 | APGE | Apogee Therapeutics, Inc. | M — Option exercise | 4.1K | $22.86 | $94K |
| 2026-05-22 | ORKA | Oruka Therapeutics, Inc. | S — Open-market sale | 13.2K | $59.97 | $794K |
| 2026-05-22 | ORKA | Oruka Therapeutics, Inc. | S — Open-market sale | 53.4K | $59.10 | $3.16M |
| 2026-05-22 | ORKA | Oruka Therapeutics, Inc. | S — Open-market sale | 38.3K | $58.43 | $2.24M |
| 2026-05-22 | ORKA | Oruka Therapeutics, Inc. | M — Option exercise | 11.7K | $11.77 | $137K |
| 2026-05-22 | ORKA | Oruka Therapeutics, Inc. | M — Option exercise | 11.9K | $7.80 | $93K |
| 2026-05-22 | ORKA | Oruka Therapeutics, Inc. | M — Option exercise | 38.7K | $6.84 | $265K |
| 2026-05-09 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 1.8K | $84.60 | $152K |
| 2026-05-09 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 3.7K | $83.92 | $311K |
| 2026-05-09 | APGE | Apogee Therapeutics, Inc. | M — Option exercise | 4.1K | $22.86 | $94K |
| 2026-04-04 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 100 | $85.89 | $9K |
| 2026-04-04 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.7K | $85.33 | $231K |
| 2026-04-04 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.7K | $84.31 | $227K |
| 2026-04-04 | APGE | Apogee Therapeutics, Inc. | M — Option exercise [10b5-1] | 4.1K | $22.86 | $94K |
Carl Dambkowski is the Chief Medical Officer at Apogee Therapeutics, Inc., a biotechnology company focused on developing biologics for various inflammatory and immunology conditions. He has been involved in multiple SEC filings related to his role but does not have notable public recognition.…
7 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 36 open-market sales ($17.97M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Dambkowski Carl profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.